The emerging role of digital biomarkers in cognitive impairment

3:00 PM - 4:00 PM, Wednesday, June 10, 2020 ・ Room 3
With digital health, we strive to improve patient outcomes by uncovering actionable insights. Digital biomarkers are playing an increasingly important role in this effort. Digital biomarkers are consumer-generated physiological, environmental, and behavioral measures collected through connected digital tools beyond physical confines of clinical environment that can be used as an indicator to explain, influence and/or predict health-related outcomes.

The panel will dive into the role of digital biomarkers and cognitive impairment, focusing on findings from a clinical feasibility study conducted by Lilly, Evidation Health and Apple, showing that an iPhone, Apple Watch, iPad, and the Beddit sleep monitoring device, in combination with digital apps may have the potential to differentiate healthy people from people with cognitive impairment. What does this mean for the future diagnosis and care for people affected by dementia?
Vice President, Chief Digital Officer
Eli Lilly and Company
Evidation Health, Co-Founder and President
Evidation Health
Deputy Director, Innovation Technology Solutions
Gates Foundation